Call for Abstract
14th Global Biomarkers Summit, will be organized around the theme “Advancements in Biomarkers from Translational Research to Commercialization Venue: HYATT PLACE AMSTERDAM AIRPORT
Venue: HYATT PLACE AMSTERDAM AIRPORT”
Biomarkers Summit 2018 is comprised of keynote and speakers sessions on latest cutting edge research designed to offer comprehensive global discussions that address current issues in Biomarkers Summit 2018
Submit your abstract to any of the mentioned tracks.
Register now for the conference by choosing an appropriate package suitable to you.
- Track 1-1Nucleic acid-based Biomarkers
- Track 1-2Protein Biomarkers
- Track 1-3Small molecule Biomarkers
- Track 1-4Lipid Biomarkers
- Track 1-5MicroRNA Biomarkers
Advancements in cancer immunotherapy have caused interest across all fields of Oncology. When working with immune checkpoint inhibitors and adoptive T-cell therapies results with less chances of repetition than regular or targeted cancer treatment are met. However, this area is still experiencing a lack of analytical and predictive Biomarkers and corresponding diagnostics. Experiments in discovering indicative Biomarkers for cancer immunotherapy involve multiple mechanisms of T-cell regulation, multiple cell types, genetic heterogeneity of cancers, immune elements, etc. The complementary and companion diagnostics for immune modulating analyses are complex and need a new systematic approach.
- Track 2-1Predictive Biomarkers to immunotherapies
- Track 2-2Mutation analysis using Biomarkers to guide therapies
- Track 2-3Biomarkers in Immune monitoring
- Track 2-4Biomarkers for precision immune-oncology
- Track 2-5Tumor Microenvironment profiling
- Track 2-6Role of Biomarkers in Cancer Vaccines development
- Track 2-7Evaluation of Biomarkers in clinical trials
- Track 2-8Biomarkers for combinational immunotherapies
- Track 2-9Tumor Neoantigens as Biomarker and target identification
- Track 2-10Liquid Biopsy for Immuno-Oncology
- Track 2-11Prognostic Biomarkers
- Track 2-12Biomarkers in Companion Diagnostics
- Track 2-13Cell proliferation Biomarkers
Biomarkers in patient selection point towards Personalized medicine. Different individual responds differently to different treatments which results in therapy’s poor outcomes. For stratification of different patients according to their treatment response molecular profiling of the individual is done. This stratification diagnostic indicates towards different Biomarkers that are identified in an individual in response to distinct treatments. With these markers identifying patients that are more likely to respond favorably to a given therapy, determining the predisposition to disease at the population level, the drug doses and the deliver time is optimized.
- Track 3-1Translating Biomarkers in Precision Medicine
- Track 3-2Translating Biomarkers into Complementary & Companion Diagnostics
- Track 3-3Genomics & proteomics evaluations: Role of Biomarkers & Case studies
- Track 3-4Biomarkers for patient stratification in pre-clinical trials
- Track 3-5Drug response test using Biomarkers
- Track 3-6Biomarkers to guide clinical decision making & molecular profiling
- Track 4-1Novel Biomarkers discovery
- Track 4-2Clinical and analytical biomarker validation
- Track 4-3Role of Biomarkers in clinical decision making
- Track 4-4Application of Biomarkers in Drug discovery and development
- Track 4-5Circulating Tumor DNA cells as Biomarkers: Case studies for various cancers
- Track 4-6Non-invasive Biomarker for dug toxicity studies
- Track 4-7Next-Generation Sequencing (NGS) assays for Translational and Clinical Research in Oncology
- Track 4-8Biomarkers in Clinical trials: Design, strategies & application case studies
Biomarkers have several uses in pharmaceutical R & D. With the recent introduction of high performance instrumentation, protein and gene arrays and bioinformatics, clinical decisions like Drug development and choosing type of treatment can be made efficiently. However, there is a lack of valid biomarkers to increase the drug development from pre-clinical through all levels of clinical studies. Biomarker in Drug Discovery can also lead to development of Personalized Medicines.
- Track 5-1Biomarkers in Autoimmune disease
- Track 5-2Biomarkers in Neuroscience
- Track 5-3Biomarkers in Oncology
- Track 5-4Biomarkers in Cardiovascular disease
- Track 5-5Biomarkers in COPD, & Respiratory diseases
- Track 5-6Biomarkers in Infectious Diseases
- Track 5-7Biomarkers in Rheumatology
- Track 5-8Biomarkers in Rare Diseases
Neurological biomarkers are present in CSF (cerebral spinal fluid), but hardly or at imperceptible levels in blood. The brain is carefully shielded by the blood–brain barrier, which protects it from damaging elements flowing in the bloodstream. Sadly for diagnostic purposes, this barricade has also made the brain’s chemistry unreachable to a fitting blood test. Neurological biomarkers can be studied using CSF, but this requires an incursive and hurting lumbar puncture technique.
- Track 6-1Biomarkers for early identification of Neurological disorders
- Track 6-2Biomarkers for monitoring of treatment efficiency & progression
- Track 6-3High performance plasma amyloid-β biomarkers in Alzheimer’s disease
Biomarkers that can monitor various immune system diseases like autoimmunity, immunodeficiency, cancer, allergy and infections are called Immunological biomarker. As the immune system interacts with every other system in the body it plays a very important role in Biomarker discovery. Immunological biomarker such as miRNA a serum Biomarkers can give information regarding immune response of a body under normal or abnormal conditions.
- Track 7-1Biomarkers for Early Progressive Inflammatory & Immunological Diseases
- Track 7-2Biomarkers as surrogate endpoints for Clinical Trials
Whenever the Heart muscles get damaged or are under some kind of stress it releases components (like proteins) in the blood. Presence of these components in blood can indicate your heart’s condition. These molecules are called Cardiovascular Biomarkers. Measuring the Biomarkers can help us monitor presence of cardiac ischemia, Acute Coronary Syndrome or the risk of having these conditions.
- Track 8-1Biomarkers for Heart Failure & Acute Coronary Syndrome
- Track 8-2Biomarkers for Metabolic Syndrome & Cardiovascular Risk
To get the coverage and reimbursement remained a primary hurdle towards the adoption of new Biomarker testes for d3edliest diseases like cancer. If certain tests are not accepted by the regulatory bodies, and insurance companies, it highly impacts the entrant of new Biomarker tests. The Centers for Medicare & Medicaid Services identified only 65 tests under the reimbursement category. Any test beyond that although useful may not reimburse hence creates a huge challenge.
- Track 9-1Policy environment for Biomarker tests for Molecularly Targeted Therapies
- Track 9-2Challenges and Issues in Biomarkers development
- Track 9-3Policy issues in development and adoption of Biomarkers for Molecularly Targeted Cancer Therapies
- Track 9-4Policy issues in the development of Personalized Medicine
- Track 9-5coverage and reimbursement issues in Cancer biomarkers
- Track 9-6Biomarkers & Drug labeling
- Track 9-7Identification of molecular Biomarkers of clinical utility
- Track 9-8Ethical, legal and social implications (ELSI) of Biomarkers
- Track 9-9Difficulties in the development of an evidence base for evaluation of Biomarkers
Personalized medicine uses an individual’s genetic profile to optimize decisions made regarding prevention, diagnosis, and medical treatment of diseases. The goal is to provide accurate therapy to the correct patient at the right time. Genomic data of an individual is the base of personalized medicine. Personalized medicine works by separating different population groups according to their molecular model. Different Biomarkers have been identified in an individual associated with different therapeutic response. Using these markers can results in complete understanding of drug doses, timing of treatment and type of treatment to be given to individual patients.
- Track 10-1Bioinformatics in Personalized Medicine.
- Track 10-2Personalized medicine using DNA biomarkers.
- Track 10-3Biomarkers and Personalized Medicine in Oncology. Treatment of cancers like GI cancer, lung cancer etc.
- Track 10-4Personalized Medicine for treating Metabolomics Disorders, Genetic disorders, neurological disorders and immune disorders.
- Track 10-5Biomarkers and personalized medicine with special focus on spinal cord injuries and dermatology.
Medical imagining for clinical decision making has been very crucial over the past decades. In medical images like X-ray, CT and MRI the trait of the image that shows the condition of health and disease of the patient is called Imaging Biomarkers. A lesion, tumor etc. on the body part that can be noticed in the medical image and can cause suspicion about certain disorder is an Imaging Biomarker itself.
- Track 11-1Imaging Technologies in Clinical Translation.
- Track 11-2Imaging Strategies and Molecular Profiling in Oncology.
- Track 11-3Imaging Techniques in Tissue Engineering.
- Track 11-4Imaging in Neuroscience.
- Track 11-5Imaging biomarkers in Cardiovascular Systems and Musculoskeletal System.
The use of Biomarkers in drug development has clinical benefits that lie in evaluating therapeutic response or in monitoring and diagnosing the activity of diseases. The discovery and validation Biomarkers serve as new surrogate endpoints in initial stage of drug trials. The components of the biomarker development process include qualification, discovery, verification, research assay optimization, commercialization and clinical validation. For development and discovery of biomarker omics techniques like metabolomics, Transcriptomics, proteomics, and genomics are used and for validation of Biomarkers computational biology, profiling techniques, data mining methods and microarray data analysis can be utilized.
- Track 12-1Mass spectrometry based biomarker discovery
- Track 12-2Protein Biomarker Discovery & Validation.
- Track 12-3Biomarkers for pediatric diseases
- Track 12-4Omics Technologies in Biomarkers Discovery and Validation. Assessment of drug response
- Track 12-5New strategies for discovery and validation of biomarkers.
Though the therapeutic effects of targeted drugs treating various cancers and other diseases are promising still there is limitation in their clinical success. The factors limiting the clinical success include both primary and acquired drug resistance including unpredictable side effects. Hence there are various researches are in progress to discover new Biomarkers for various disease starting from autoimmune disorders to cardiovascular and Cancers.
- Track 13-1Emerging therapeutic biomarkers in Cancers: Endometrial Cancer, Ovarian cancer, Melanoma, Non-small cell lung cancer, Endometrial Carcinoma, Lung Cancer etc.
- Track 13-2Emerging Biomarkers in various diseases: Autoimmune hepatitis, Alzheimer’s disease, Renal Damage, Lymphangioleiomyomatosis, HDL Cholesterol, Cardiovascular Diseases, Necrotizing Methicillin‐Resistant Staphylococcus aureus Pneumonia, systemic sclerosis
- Track 13-3Emerging Biomarkers for personalized immunotherapies
- Track 13-4Cancer epigenetics as an emerging Biomarker
- Track 13-5Role of Emerging Biomarkers towards Unraveling the Complex Biology of various diseases
There are many circulating components found in biofluid but the one gaining significant attention is Exosomes. Exosomes are extracellular vesicles released from cells when an intermediate endocytic compartment fuses with the plasma membrane. It is found in almost all biological fluids like blood, urine, saliva, serum, breast milk etc. These acts as a mediator of cell to cell communication as they transfer bioactive molecules like lipids, nucleic acids, proteins etc. to the other cells. As they carry important molecular information like nucleic acid and protein they show the source of cell and indicate if there is any presence of abnormal cells, hence acting as a Biomarker.
- Track 14-1Exosomes and nanotheranostics.
- Track 14-2Exosome-based approaches for diagnosis of cancers like: Colorectal Cancer and gastrointestinal cancer.
- Track 14-3Exosomes and diagnosis of diseases like prion diseases, Epstein–Barr virus (EBV), kidney-related diseases etc.
- Track 14-4Circulating Exosomes as new biomarkers for neurodegenerative disease or brain injury diagnosis.
- Track 14-5Exosomal biomarkers for monitoring immunological rejection of tissue grafts.
- Track 14-6Exosomal microRNAs as biomarkers.
Genetic-based Biomarkers are nothing but DNA or sequence based Biomarkers that can provide genetic information of the person. Next-Generation Sequencing has allowed researchers to sequence individual genomes and compare several mutations with specific diseases. Cancer being an inherent disease of the genome, it is expected of NGS technology to be applied in the area cancer for better understanding of carcinogenesis. NGS can also be used for analysis and validation of sequence based biomarker. It further assists in development of a more precise Personalized medicine.
- Track 15-1NGS for the discovery of Biomarkers
- Track 15-2MicroRNA sequencing for the prediction of diseases
- Track 15-3SNP as Biomarkers
- Track 15-4Cytogenetic & Oxidative stress Biomarkers
- Track 15-5Genetic-based Biomarkers and NGS in personalized care of Cancer
Efficiency of mobile health or mhealth techniques in collecting, integrating, analyzing health related data has given rise to a cost and time effective sensor called Digital Biomarkers. Digital Biomarkers have ascended from Patient-facing devices. These uses machine learning techniques and smartphone sensing technologies to monitor users’ health status such as heart rate and blood pressure. They can also be used to check their mental health by collecting and analyzing data regarding mobile phone usage patterns, mobility and communication. Their aim is to reduce the damage cause by computer models and wearable sensors and to make clinical trials more precise.
- Track 16-1Biosensors & wearables as Biomarker: Clinical development, Applications & Case studies
- Track 16-2Digital end points in clinical trials
- Track 16-3Mobile Health (m-health) in clinical trials
- Track 16-4Digital Biomarkers in drug development
- Track 16-5Regulatory aspects for medical app development: Commercialization and Clinical Trial Use
- Track 16-6Machine learning & Internet of Things (IoT) application in Digital Biomarkers